(breadfruit) seeds contain three different lectins (Frutalin, Frutapin (FTP) and Frutackin) with distinct carbohydrate specificities. The most abundant lectin is Frutalin, an α-D-galactose-specific carbohydrate-binding glycoprotein with antitumour properties and potential for tumour biomarker discovery as already reported. FTP is the second most abundant, but proved difficult to purify with very low yields and contamination with Frutalin frustrating its characterization. Here, we report for the first time high-level production and isolation of biologically active recombinant FTP in BL21, optimizing conditions with the best set yielding >40 mg/l culture of soluble active FTP. The minimal concentration for agglutination of red blood cells was 62.5 µg/ml of FTP, a process effectively inhibited by mannose. Apo-FTP, FTP-mannose and FTP-glucose crystals were obtained, and they diffracted X-rays to a resolution of 1.58 (P222), 1.70 (P321) and 1.60 (P321) Å respectively. The best solution showed four monomers per asymmetric unit. Molecular dynamics (MD) simulation suggested that FTP displays higher affinity for mannose than glucose. Cell studies revealed that FTP was non-cytotoxic to cultured mouse fibroblast 3T3 cells below 0.5 mg/ml and was also capable of stimulating cell migration at 50 µg/ml. In conclusion, our optimized expression system allowed high amounts of correctly folded soluble FTP to be isolated. This recombinant bioactive lectin will now be tested in future studies for therapeutic potential; for example in wound healing and tissue regeneration.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520216 | PMC |
http://dx.doi.org/10.1042/BSR20170969 | DOI Listing |
Alzheimers Dement
December 2024
Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Background: New methods developed to estimate when AD biomarkers became abnormal in individuals have shown considerable heterogeneity in amyloid and tau pathology onset age. This work used polygenic scores (PGS) generated from CSF Aβ and ptau GWAS, individual-level genetic data, and estimated tau onset age (ETOA) to identify genetic influences on tau onset beyond APOE.
Method: Participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI) with genetic data, CSF biomarkers (Aβ and ptau), and longitudinal [F]Flortaucipir (FTP) tau PET were analyzed (N = 462).
Alzheimers Dement
December 2024
University of California, Berkeley, Berkeley, CA, USA.
Background: The amyloid cascade hypothesis posits a sequence of events proceeding from amyloid-β (Aβ) deposition to entorhinal cortical (EC) tau to neocortical (meta-temporal) tau. This study examined how genetics may modify relationships between these variables on the AD pathway.
Methods: We used causal path analyses to model effects of sex, APOE-ε4 (0,1,2 alleles), and genetic risk for neuroinflammation on Aβ, EC tau and meta temporal tau.
Alzheimers Dement
December 2024
College of Public Health, University of Kentucky, Lexington, KY, USA.
Background: We recently reported genetic associations with dementia-related proteinopathies. Using multidimensional generalized partial credit modeling, we constructed three continuous latent variables, corresponding to TDP-43, Aβ/Tau, and a-synuclein related neuropathology endophenotype scores.
Method: Participant data were drawn from the National Alzheimer's Coordinating Center (NACC) neuropathology (NP) data (from the September 2023 data freeze) linked to Alzheimer's Disease Genetics Consortium (ADGC) genotype data.
Alzheimers Dement
December 2024
Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Background: Accelerated long-term forgetting (LTF) is characterized by unimpaired retention of information after short-term delays (e.g., 20-30 minutes) with increased forgetting at longer intervals (e.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Georgia State University, Atlanta, GA, USA.
Background: Beginning new Alzheimer's disease (AD) treatments before AD symptoms are prominent would optimize the benefits of these disease slowing treatments. To accomplish this goal, clinicians must identify measures of early disease progression. As a step in doing this, we set out to characterize the relationships between cognitive complaints, wellbeing, cognitive performance, and metacognitive calibration in older adults in order to inform a model of cognition in typical older adults.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!